Why Is CREDO TECHNOLOGY GRO (CRDO) Stock Down Today?

CRDO stock fell 5.36% to $206.93 on Friday, marking a sharp reversal after a recent rally. The decline came amid a price target cut from Stifel, which lowered its target to $310 from $350. The stock opened with a modest 0.6% gap up but quickly reversed course, hitting a session low of $206.06 before settling near that level. The move reflects investor reaction to the updated analyst outlook and broader market volatility.

What Happened

Stifel’s downgrade of Credo Technology’s stock price target was the most immediate catalyst for the drop. The firm maintained a Buy rating but reduced its target to $310 from $350, signaling concerns about valuation. This came after the stock had already surged 14.9% over the previous eight sessions, reaching $222.66. The stock’s intraday trajectory showed a brief initial strength but a rapid decline as the session progressed. By the end of the day, CRDO was trading near its session low, with volume at 1.0 million shares, or 0.1 times the 3-month average.

The broader market context included a weak Nasdaq 100 and mixed performance among peers. Credo Technology, which is transitioning from copper-based products to optical transceivers, has seen strong revenue growth, with triple-digit year-to-date increases. However, the recent analyst move has raised questions about whether the stock’s valuation is aligned with its fundamentals.

What The Data Shows

CRDO’s fundamentals remain strong, with a trailing twelve-month revenue growth of 165.1% and a net margin of 33.8%. However, the stock trades at a P/E ratio of 77.2, reflecting high expectations. The stock’s volatility is underscored by its beta of 3.23 and a 52-week range of $86.48 to $308.67. Intraday activity showed a sharp reversal after a modest opening gap up. The stock also hit eight fresh 52-week lows on October 5, indicating continued pressure from sellers.

What To Watch

Investors will be watching for further analyst updates and any developments in Credo Technology’s optical product line. The stock’s recent performance and valuation adjustments suggest ongoing scrutiny from market participants.